Quantcast
Last updated on April 18, 2014 at 10:45 EDT

Latest Vancomycin Stories

2011-05-16 21:56:56

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers. The study will be presented at the ATS 2011 International Conference in Denver. "At the end of the treatment period in this study, linezolid offered statistically significant higher rates of clinical and microbiologic...

2011-05-12 15:30:00

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID(TM) (fidaxomicin), an investigational antibiotic for the treatment of Clostridium difficile Infection (CDI), at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The analysis showed that...

6f6f01f50dce61ce4d046b454ee6eba7
2011-05-12 06:40:00

Despite the fact that bedbugs are generally not viewed as a major public health threat, drug-resistant staph bacteria has been found in bedbugs from three hospital patients from a subjugated neighborhood in Vancouver by a team of Canadian scientists. Although bedbugs are not known to spread disease, they do lead to scratching, which may cause the skin to tear and make people at risk for bacteria, said Dr. Marc Romney, an author on the study. A study published Wednesday in the journal...

2011-05-11 20:26:00

SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received. CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been...

2011-05-10 07:45:00

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID(TM) (fidaxomicin) for the treatment of Clostridium difficile infection (CDI). The data resulted from analysis of specific risk factors associated with negative outcomes in patients...

2011-05-09 12:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 2011 Digestive Disease Week (DDW) conference highlighting additional analyses of data from Phase 3 trials of DIFICID(TM) (fidaxomicin), an investigational product for the treatment of Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) The first analysis aimed to identify risk factors associated with...

2011-05-04 08:01:00

CLEVELAND, May 4, 2011 /PRNewswire/ -- Ganeden Biotech announced today that the company will present new in vivo data on the effect of its GanedenBC30 probiotic strain in C. diff infection at the Digestive Disease Week (DDW) conference in Chicago, Ill., from May 7-10, 2011. Jointly with its collaborator, Dr. Leo R. Fitzpatrick, Associate Professor from the Department of Pharmacology, Penn State College of Medicine, Pa., Ganeden will present data on the effect of GanedenBC30 on impacting C....

2011-04-28 07:00:00

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID(TM) Phase 3 trials will be presented at the following medical meetings: Digestive Disease Week (DDW), McCormick Place, Chicago, IL May 7-10, 2011 Poster Presentation Information: Risk of Recurrence and Time to Recurrence Following Title: Treatment of Clostridium difficile Infection:...

2011-04-27 10:00:00

EXTON, Pa., April 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 36th Annual Healthcare Conference at 10:40 A.M. ET on Tuesday, May 3, 2011. The conference is being held at the InterContinental Hotel in Boston, MA. Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America/Merrill Lynch 2011...

2011-04-20 14:00:00

EXTON, Pa., April 20, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2011 are expected to be released on Thursday, April 28, 2011 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2011 first quarter financial results and other business. The press release and the live...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »